H.PIO Co., Ltd. (KOSDAQ:357230)
South Korea · Delayed Price · Currency is KRW 2,080.00
+15.00 (0.73%)
At close: Sep 11, 2026
H.PIO Revenue
H.PIO had revenue of 78.49B KRW in the quarter ending June 30, 2026, with 4.83% growth. This brings the company's revenue in the last twelve months to 269.63B, up 6.95% year-over-year. In the year 2025, H.PIO had annual revenue of 258.19B with 6.32% growth.
Revenue (ttm)
269.63B
Revenue Growth
+6.95%
P/S Ratio
0.32
Revenue / Employee
3.69B
Employees
73
Market Cap
85.49B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 258.19B | 15.36B | 6.32% |
| Dec 31, 2024 | 242.83B | 10.80B | 4.66% |
| Dec 31, 2023 | 232.03B | 36.05B | 18.39% |
| Dec 31, 2022 | 195.98B | 36.54B | 22.92% |
| Dec 31, 2021 | 159.43B | 16.65B | 11.66% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| DongKoo Bio & Pharma | 241.43B |
| Daehan Nupharm | 211.48B |
| WITHUS PHARMACEUTICAL Co.,LTD. | 111.72B |
| OPTUS Pharmaceutical | 94.47B |
| KOREA PHARMA | 93.94B |
| Sam-A Pharm. | 72.28B |
| Polaris AI Pharma | 63.94B |
| Samik Pharmaceutical Company LTD. | 62.26B |